ProFound Therapeutics and Novartis Join Forces to Develop New Heart Disease Treatments

ProFound Therapeutics, in collaboration with Novartis

Image Credits: PharmaLive

Which New Collaboration is Currently Streaming in the Healthcare Market?

ProFound Therapeutics company focused on the human proteome to discover new medicines for various diseases, has entered into a collaboration with Novartis for four years to develop and introduce novel therapeutics for cardiovascular diseases to accelerate its ProFoundry platform. The collaboration will bring forward innovative solutions for a population of patients by approaching ProFound’s outstanding ability to recognize novel proteins from the extensive proteome as drug targets and drugs with Novartis’ excellent cardiovascular drug development expertise. Novartis withstands through the continued commitment, supporting individuals with cardiovascular diseases.

ProFoundry Platform and Agreement

The ProFoundry platform integrates different sources of biological data with computationally advanced tools to investigate, validate, and explore the richest source of proteins. The proteins that have not been revealed yet to elucidate novel protein, drug findings, and the human proteome.

The four-year collaboration agreement’s terms state that Profound will receive $25 million in near-term and upfront payments, along with the transaction value of $750 million, according to the selected target. Also liable for tiered royalties.

Innovation

Innovation is bolstering the healthcare market and management. It has strengthened the existing solutions and extended the chain of engagement. This new collaboration is initiating a solution for a vast population of patients. Both companies' specialization and expertise are enhancing internal economic growth while also making efforts to explore new areas. Innovation represents a new advancement to establish a position in the healthcare market.

Views and Statements

MD, CEO of Profound Therapeutics and flagship pioneering CEO-partner, John Lepore, said, “We are excited for the partnership with Novartis, a company known for its cardiovascular innovation, which is a popular discussion in the industry.” Further, “The collaboration is a validation of our company’s potential for a profoundry platform. This partnership encouraged us to shift the traditional discovery approach to a huge and undiscovered biology of the human proteome. Novartis and Profound together have an opportunity to elevate the contribution to the development and explore new targets to introduce transformative therapies to identify the global tension of cardiovascular diseases.”

PhD, President, Biomedical research at Novartis, Fiona Marshall said, “The company is highly committed to addressing novel therapeutic targets to develop and explore innovative medicines for patients suffering from cardiovascular diseases. Novartis is thrilled to collaborate with Profound, and we will be merging our capabilities and expertise to discover under-researched biology, translate science into effective treatment, and explore new mechanisms.”